1. Home
  2. SLXN vs HAO Comparison

SLXN vs HAO Comparison

Compare SLXN & HAO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLXN
  • HAO
  • Stock Information
  • Founded
  • SLXN 2008
  • HAO 2018
  • Country
  • SLXN Israel
  • HAO China
  • Employees
  • SLXN N/A
  • HAO N/A
  • Industry
  • SLXN
  • HAO
  • Sector
  • SLXN
  • HAO
  • Exchange
  • SLXN NYSE
  • HAO NYSE
  • Market Cap
  • SLXN 7.3M
  • HAO 3.3M
  • IPO Year
  • SLXN N/A
  • HAO 2024
  • Fundamental
  • Price
  • SLXN $0.87
  • HAO $1.35
  • Analyst Decision
  • SLXN Strong Buy
  • HAO
  • Analyst Count
  • SLXN 1
  • HAO 0
  • Target Price
  • SLXN $5.00
  • HAO N/A
  • AVG Volume (30 Days)
  • SLXN 127.2K
  • HAO 27.9K
  • Earning Date
  • SLXN 08-21-2025
  • HAO 07-18-2025
  • Dividend Yield
  • SLXN N/A
  • HAO N/A
  • EPS Growth
  • SLXN N/A
  • HAO N/A
  • EPS
  • SLXN N/A
  • HAO 0.19
  • Revenue
  • SLXN N/A
  • HAO $48,970,924.00
  • Revenue This Year
  • SLXN N/A
  • HAO N/A
  • Revenue Next Year
  • SLXN N/A
  • HAO N/A
  • P/E Ratio
  • SLXN N/A
  • HAO $7.53
  • Revenue Growth
  • SLXN N/A
  • HAO 15.04
  • 52 Week Low
  • SLXN $0.58
  • HAO $0.84
  • 52 Week High
  • SLXN $41.85
  • HAO $173.25
  • Technical
  • Relative Strength Index (RSI)
  • SLXN N/A
  • HAO 51.38
  • Support Level
  • SLXN N/A
  • HAO $1.29
  • Resistance Level
  • SLXN N/A
  • HAO $1.49
  • Average True Range (ATR)
  • SLXN 0.00
  • HAO 0.10
  • MACD
  • SLXN 0.00
  • HAO 0.02
  • Stochastic Oscillator
  • SLXN 0.00
  • HAO 65.14

About SLXN BIOMOTION SCIENCES

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

About HAO HAOXI HEALTH TECHNOLOGY LTD

Haoxi Health Technology Ltd is an online marketing solution provider in China, with an advertiser client base mainly in the healthcare industry. Haoxi has been rooted in the field of local online effect marketing for many years, serving customers in various industries at home and abroad, and its main business is the medical industry. It generates its revenue by providing one-stop online marketing solutions, in particular online short video marketing solutions, to advertisers through its media partners. The company provides customized marketing solutions by planning, producing, placing, and optimizing online ads, especially online short video ads, to help its advertisers acquire, convert, and retain ultimate consumers on various online media platforms.

Share on Social Networks: